Proteomics International has launched PromarkerEso at the ISDE World Congress in Brisbane (18–20 September). PromarkerEso is a world-first protein biomarker-based blood diagnostic that can rule out esophageal adenocarcinoma (EAC). A paper on the technology was also published in the journal Proteomes.
Esophageal cancer (EAC) is one of the deadliest forms of cancer, with Barrett’s esophagus—a precursor affecting up to 2% of adults—often going undiagnosed. PromarkerEso addresses this critical gap by enabling earlier detection in a primary care setting, improving access to prompt diagnosis and treatment, and identifying risks that may be presently missed.
